BBK Worldwide Launches Patient Travel Program
BBK Worldwide announced the availability of RSG® Arrive, a full-service concierge program created to more fully support clinical trial patients
BBK Worldwide announced the availability of RSG® Arrive, a full-service concierge program created to more fully support clinical trial patients and operationalize travel for pharmaceutical companies, especially important for rare disease studies where recruitment of patients extends well beyond the area of the site, often in different countries. The latest offering within the company’s RSG® Suite of engagement services, RSG Arrive manages all travel-related logistics operational and financial for trial patients and sites. From car and shuttle booking, to international flight and accommodation management, RSG Arrive ensures that patients get to and from study visits as simply and seamlessly as possible.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
